TERN Terns Pharmaceuticals, Inc. Insider Trading

TERN CEO Burroughs sells 14,583 shares for $681,108.26 on 2026-03-16; stock up 23% in 30 days, near 52-week high of $47.09.

CEO Amy L. Burroughs executed two separate sales totaling 14,583 shares for $681,108.26, reducing her holdings from 303,559 to 288,976 shares (-4.8%). The sales occurred at $46.57 and $47.30 per share—just below the 52-week high of $47.09—as the stock has rallied +23.0% over the prior 30 days. The timing occurs on an unprofitable company (net income $-24.6M) with revenue declining -100.0% year-over-year, suggesting material operational headwinds. Her same-ticker selling pattern shows three recent sales on 2026-02-17 with outcomes still pending, and an inconsistent historical timing record at TERN (2 of 2 measurable prior sells posted small positive 30-day returns). The convergence of peak valuation, deteriorating fundamentals, and sequential selling activity warrants examination of insider confidence relative to the company's financial trajectory.

CEO Amy L. Burroughs sold 14,583 shares (14.6K) at blended $39.19 on Feb 17, reducing stake 4.8% to 288,976 shares.

CEO Amy L. Burroughs executed 3 separate sales totaling 14,583 shares for $571,579.08 on a single day at prices ranging from $38.07 to $39.80, just below the current market price of $39.35. This transaction is notable in the context of Terns' fundamentals: the company reported a net loss of $-24,635,000.00 over its most recent full fiscal year with annual revenue growth of -100.0%, yet the stock has appreciated 50.7% over the past 90 days and trades 16.4% below its 52-week high of $47.09. At this ticker, Burroughs' prior 3 sales (executed Jan 5 and Jan 15) showed modest near-term returns (+2.1%, +0.7%, -5.4% at the 30-day mark), and only 1 of her 2 measurable buy outcomes at TERN was well-timed; her cross-ticker sell track record averaged -0.9% returns over 30 days. The sale reduces her holdings from 303,559 to 288,976 shares—a modest reduction—during a period of strong recent price momentum against a backdrop of ongoing losses.

CEO Burroughs sold 68,749 shares at avg $37.07 (totaling $2.5M), reducing stake by 19.2% to 288,976 shares

Amy L. Burroughs, Chief Executive Officer of Terns Pharmaceuticals, executed 2 separate sales on 2026-01-15 totaling 68,749 shares for $2,548,602.83 at a blended average price of $37.07. The sale reduced her holdings by 19.2%, from 357,725 shares to 288,976 shares. This transaction occurs against a challenging fundamental backdrop: the company reported a full-year net income of $-24,635,000.00 (negative, unprofitable) and annual revenue declined 100.0%, while the stock has retreated 22.3% from its 52-week high of $47.09 (trading currently at $36.60). At the same-ticker level, Burroughs' prior sell on 2026-01-05 is not yet measurable, but her prior buys at TERN show mixed outcomes (one 90-day return of +94.0%, another of -49.2%, indicating inconsistent execution). The magnitude of this 68.7K-share liquidation, combined with negative profitability and revenue contraction, warrants examination of whether this reflects portfolio rebalancing or a shift in conviction toward the company's near-term trajectory.

CEO Amy L. Burroughs sold 71,339 shares of TERN at $38.10 on 2026-01-05, reducing stake 33.9%; company unprofitable with -$24.6M net income.

Amy L. Burroughs, CEO of Terns Pharmaceuticals, sold 71,339 shares for $2,718,229.92, reducing her holdings from 210,315 shares to 138,976 shares. The sale represents a 33.9% reduction in her position at $38.10 per share, occurring as the stock trades at $38.32 (off its 52-week high of $47.09). The timing is notable given that prior TERN-specific trades show mixed results: a June 2025 buy appreciated 56.3% in 30 days and 94.0% in 90 days, while a December 2024 buy declined 19.6% and 49.2% respectively. Against the backdrop of the company's negative $24.6M net income over its most recent full fiscal year and zero year-over-year revenue growth, a material stake reduction by the CEO warrants attention to underlying business momentum and competitive positioning.

CFO Gengos Andrew purchased 10,000 shares at $3.93 (2 separate transactions totaling $39,283.00) at TERN, growing holdings 66.7%

Andrew Gengos, CFO of Terns Pharmaceuticals, executed 2 separate purchases totaling 10,000 shares for $39,283.00 at a blended average price of $3.93 on 2025-06-27, raising his post-transaction holdings to 25,000 shares from 15,000 shares (a +66.7% increase). The purchase price of $3.93 is modestly above the current price of $3.73 but well below the 52-week high of $11.23, reflecting a stock trading -66.8% from its peak. Most materially, Terns Pharmaceuticals reported a net income of $-23,908,000.00 and annual revenue growth of -100.0%, indicating the company is unprofitable and has contracted significantly. The insider's recent trading pattern at TERN shows 3 prior buys within the past two weeks (2025-06-13 and 2025-06-16), with outcomes not yet measurable at either the 30-day or 90-day horizon, leaving open questions about the basis for this accumulation amid deteriorating fundamentals.

CEO Amy L. Burroughs bought 23,314 shares of TERN at $3.87; stock +34.4% in 30d but CEO's prior 2 TERN buys underperformed (90d: -19.6%, -27.8%).

Chief Executive Officer Amy L. Burroughs purchased 23,314 shares at $3.87, doubling her holdings from 23,769 to 47,083 shares. The acquisition occurred against a backdrop of company fundamentals showing negative net income of -$23,908,000.00 and zero annual revenue growth (declining -100.0% year-over-year), raising questions about the investment rationale during operational distress. Her prior trades at TERN show a poor timing record: a December 2024 buy declined 19.6% in 30 days and 49.2% over 90 days, and a November 2024 buy delivered -27.8% over 90 days, with zero of two prior TERN purchases proving well-timed at the 90-day mark. While the stock has risen 34.4% over the past 30 days from its $2.00–$11.23 range, this recent recovery does not offset the persistent underperformance pattern in the insider's transaction history at this security.

CFO Gengos Andrew buys 15,000 shares across 3 transactions for $57,082.50 at blended average $3.81

Gengos Andrew, CFO of Terns Pharmaceuticals, purchased 15,000 shares (15.0K shares) across 3 separate transactions on June 13-16, 2025, at prices of $3.75, $3.72, and $3.95, totaling $57,082.50. The timing coincides with stock movement—the 30-day price change is +39.2%—and his post-transaction holdings now stand at 15,000 shares versus zero prior. The company faces significant headwinds: net income is $-23.9M and annual revenue growth is -100.0%, indicating the firm is unprofitable and has no top-line revenues to report. The 52-week range of $2.00–$11.23 shows the stock is currently -64.3% from its high, creating a substantially different risk-reward context than when earlier buyers entered. This purchase represents the CFO's first material position stake in the company and occurs in a period of compressed profitability and negative revenue trajectory, warranting review of the business rationale and any concurrent disclosure of strategic initiatives.

CBP Jung Melita Sun buys 2,250 shares of TERN at $5.11 amid -100.0% revenue decline and $-21.9M net loss.

Jung Melita Sun, as Chief Business Officer, purchased 2,250 shares at $5.11 on 2024-11-30, establishing an initial open-market position in TERN. The company faces severe financial headwinds: full-year revenue declined -100.0% year-over-year and net income totaled $-21.9M, indicating the company is unprofitable. The stock has declined significantly from its 52-week high, trading at $4.37 (down 30-day: -24.0%, 90-day: -39.0%). This insider purchase from a C-suite executive occurs within a context of material deterioration in the company's financial performance and substantial stock weakness, warranting attention to whether this reflects management's forward-looking perspective on business trajectory.

TERN CEO Amy L. Burroughs buys 510 shares at $5.11, raising stake to 19,609 shares amid -61.1% decline from 52-week high

Burroughs purchased 510 shares of Terns Pharmaceuticals at $5.11 on 2024-11-30, a modest 2.7% increase to her 19,609-share position. The transaction occurred in a severely depressed environment: the stock trades at $4.37, down 61.1% from its 52-week high of $11.23, with a 30-day decline of 24.0% and 90-day decline of 39.0%. Fundamentally, the company reported negative net income of $-21,945,000.00 and experienced annual revenue growth of -100.0%, indicating operational distress. The CEO's cross-ticker track record shows limited buy activity with an average 30-day return of -19.6%, and her single prior TERN transaction (a buy on 2024-12-05) has already declined 19.6% within 30 days, raising questions about timing effectiveness in this volatile, unprofitable company.

CEO Amy L. Burroughs bought 15,450 shares of TERN at $7.15 on 2024-12-05, expanding stake 423.4%; stock now down -41.4% from 52-week high.

Amy L. Burroughs, Chief Executive Officer of Terns Pharmaceuticals, purchased 15,450 shares at $7.15 on 2024-12-05, raising her holdings from 3,649 to 19,099 shares (+423.4% increase). This represents a material commitment of $110,467.50 by the company's top executive at a time when the stock is trading at $6.58, down -41.4% from its 52-week high of $11.23. Notably, Terns is unprofitable with full-year net income of -$21,945,000.00 and zero annual revenue growth (-100.0% year-over-year), creating a backdrop of operational challenges. The CEO's purchase just five days after a prior buy on 2024-11-30 suggests sustained or escalating conviction during a period of significant stock deterioration, though the recent 90-day decline of -41.4% frames this acquisition in a depressed price environment.